Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Droplet-based single cell RNAseq tools: a practical guide.

Salomon R, Kaczorowski D, Valdes-Mora F, Nordon RE, Neild A, Farbehi N, Bartonicek N, Gallego-Ortega D.

Lab Chip. 2019 May 14;19(10):1706-1727. doi: 10.1039/c8lc01239c.

PMID:
30997473
2.

Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology.

Valdes-Mora F, Handler K, Law AMK, Salomon R, Oakes SR, Ormandy CJ, Gallego-Ortega D.

Front Immunol. 2018 Nov 12;9:2582. doi: 10.3389/fimmu.2018.02582. eCollection 2018. Review.

3.

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.

Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ.

Nat Commun. 2017 Nov 7;8(1):1346. doi: 10.1038/s41467-017-01393-8.

4.

Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer.

Valdés-Mora F, Locke WJ, Bandrés E, Gallego-Ortega D, Cejas P, García-Cabezas MA, Colino-Sanguino Y, Feliú J, Del Pulgar TG, Lacal JC.

Oncotarget. 2017 Apr 18;8(16):26755-26770. doi: 10.18632/oncotarget.15815.

5.

Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer.

Stirzaker C, Song JZ, Ng W, Du Q, Armstrong NJ, Locke WJ, Statham AL, French H, Pidsley R, Valdes-Mora F, Zotenko E, Clark SJ.

Oncogene. 2017 Mar;36(10):1328-1338. doi: 10.1038/onc.2016.297. Epub 2016 Sep 5.

PMID:
27593931
6.

H2A.Z acetylation and transcription: ready, steady, go!

Colino-Sanguino Y, Clark SJ, Valdes-Mora F.

Epigenomics. 2016 May;8(5):583-6. doi: 10.2217/epi-2016-0016. Epub 2016 Apr 18. No abstract available.

7.

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ.

PLoS Biol. 2015 Dec 30;13(12):e1002330. doi: 10.1371/journal.pbio.1002330. eCollection 2015 Dec.

8.

Prostate cancer epigenetic biomarkers: next-generation technologies.

Valdés-Mora F, Clark SJ.

Oncogene. 2015 Mar 26;34(13):1609-18. doi: 10.1038/onc.2014.111. Epub 2014 May 19. Review.

PMID:
24837368
9.

Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer.

Stone A, Valdes-Mora F, Clark SJ.

Epigenomics. 2013 Dec;5(6):595-8. doi: 10.2217/epi.13.70. No abstract available.

10.

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.

Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA.

Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16.

11.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

12.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

13.

Lineage specific methylation of the Elf5 promoter in mammary epithelial cells.

Lee HJ, Hinshelwood RA, Bouras T, Gallego-Ortega D, Valdés-Mora F, Blazek K, Visvader JE, Clark SJ, Ormandy CJ.

Stem Cells. 2011 Oct;29(10):1611-9. doi: 10.1002/stem.706.

14.

Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer.

Valdés-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, Nair SS, Patterson KI, Tremethick DJ, Stirzaker C, Clark SJ.

Genome Res. 2012 Feb;22(2):307-21. doi: 10.1101/gr.118919.110. Epub 2011 Jul 25.

15.

Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.

Gallego-Ortega D, Gómez del Pulgar T, Valdés-Mora F, Cebrián A, Lacal JC.

Adv Enzyme Regul. 2011;51(1):183-94. doi: 10.1016/j.advenzreg.2010.09.010. Epub 2010 Oct 28. Review.

PMID:
21035492
16.

Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC.

PLoS One. 2009 Nov 12;4(11):e7819. doi: 10.1371/journal.pone.0007819.

17.

TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer.

Valdés-Mora F, Gómez del Pulgar T, Bandrés E, Cejas P, Ramírez de Molina A, Pérez-Palacios R, Gallego-Ortega D, García-Cabezas MA, Casado E, Larrauri J, Nistal M, González-Barón M, García-Foncillas J, Lacal JC.

Ann Surg Oncol. 2009 Jan;16(1):78-87. doi: 10.1245/s10434-008-0166-x. Epub 2008 Nov 11.

PMID:
19002529
18.

Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism.

Gómez Del Pulgar T, Valdés-Mora F, Bandrés E, Pérez-Palacios R, Espina C, Cejas P, García-Cabezas MA, Nistal M, Casado E, González-Barón M, García-Foncillas J, Lacal JC.

Int J Oncol. 2008 Jul;33(1):185-93.

PMID:
18575765
19.

Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer.

Gómez del Pulgar T, Bandrés E, Espina C, Valdés-Mora F, Pérez-Palacios R, García-Amigot F, García-Foncillas J, Lacal JC.

Int J Biochem Cell Biol. 2007;39(12):2289-302. Epub 2007 Jul 4.

PMID:
17766170

Supplemental Content

Loading ...
Support Center